Aloe vera supplementation improves cardiovascular risk factors in hemodialysis patients: A randomized, double-blind, placebo-controlled trial.
Avicenna J Phytomed
; 14(4): 422-430, 2024.
Article
en En
| MEDLINE
| ID: mdl-38952774
ABSTRACT
Objective:
This study assessed the effects of Aloe vera supplementation on serum inflammatory factors, blood sugar and lipid profiles in hemodialysis patients. Materials andMethods:
Totally, 50 hemodialysis patients were allocated randomly to either Aloe vera or placebo groups. The Aloe vera group received 2 Aloe vera capsules daily for 8 weeks (500 mg/day). Serum C-reactive protein (hs- CRP), Fasting blood glucose (FBS), and lipid profiles levels were evaluated at the baseline and the end of the eighth week.Results:
Aloe vera supplementation for 8 weeks was associated with a significant reduction of serum hs- CRP (p=0.004), total cholesterol (p=0.01), low density lipoprotein (LDL) (p=0.02) leves and increased high density lipoprotein (HDL) (p=0.002) concentration in the hemodialysis patients.Conclusion:
Aloe vera supplementation is beneficial in improvement of cardiovascular risk factors in hemodialysis patients.
Texto completo:
1
Base de datos:
MEDLINE
Idioma:
En
Revista:
Avicenna J Phytomed
Año:
2024
Tipo del documento:
Article
País de afiliación:
Irán